EJHST

Egyptian Journal of Health Sciences Technology

Article

Modern Technology as a Catalyst for Transformation in the Pharmaceutical Industry: A Review and Future Vision

Eman Hassan Elsayed[1*]

[1] Faculty of Applied Health Sciences, Borg Al Arab Technological University (BATU), Alexandria, Egypt

Abstract— **Pharmaceutical industry plays a crucial role in promoting global health across the whole world. This happens through the development of innovative treatments, medications, and therapies. The presence of technological advancements nowadays has revolutionized the pharmaceutical industry by driving significant progress in drug discovery, manufacturing processes, supply chain management, and patient care. The industry confronted with growing obstacles, including as the prevalence of chronic illnesses, which the WHO estimates account for 71% of all deaths worldwide, and the restricted availability of necessary medications for more than 2 billion people globally. As a result, cutting-edge technologies like biotechnology, robotics, artificial intelligence, and digital health platforms have become revolutionary instruments at every point of the pharmaceutical value chain. For example, AI reduced early-stage drug discovery timelines by up to 50%, while automation and advanced analytics have significantly improved manufacturing efficiency and quality control. This review highlights the impact of these technological advancements on drug development, production, distribution, and explores their potential to reshape the future of pharmaceutical care in a more precise, efficient, and patient-centered direction. analyzing the impact of emerging technologies and their potential to reshape the way of development and delivery of medications.**

Keywords— **Pharmaceutical industry, Drug Development, Technology, Artificial intelligence.**

I. INTRODUCTION

In recent decades, there have been notable transformations in the operational structure and presence of the pharmaceutical and biopharmaceutical industry. The development of the pharmaceutical sector has been significantly influenced by technical breakthroughs, which are crucial for enhancing human health [1-3].

Many research studies have explored the declining productivity within the industry, the transformation of commercial models, and the increasing importance of emerging markets as substantial revenue sources. The pharmaceutical sector is shifting from its existing model to a more streamlined and targeted approach, establishing a research presence in crucial innovation bio-clusters and experiencing a growing income from biologics and specialty products in emerging markets[1-4].

The pharmaceutical industry will also have to deal with stricter regulatory processes for new drug approval and increased government monitoring of the ongoing sale of current medications. There is little doubt that when approving new medications for sale, regulators will pay more attention to patient safety and benefits [1-4].

Research shows that there is a special emphasis on pharmaceutical research and development (R&D), as this is thought to be a crucial component of a drug's success. This feature of the industry is a result of research and development efforts, which include lengthy clinical trial approval processes and regulatory authority approval processes. Furthermore, there is a compelling motivation for companies to promote their products within the patented duration. In Japan, the research and development process spans from nine to sixteen years, while patent protection typically endures for twenty to twenty-five years. Factoring in costs related to discontinued projects, the average expenditure for developing a new medication is approximate to range between $1 billion and $1.2 billion USD [1-4].

In the upcoming years, the big pharma model is expected to be impacted by the convergence of healthcare and information technology. With major businesses like Apple and Google acting as disruptive forces, the impact of big data and mobile health on diagnostics and healthcare is growing. The integration of companion diagnostics with medications has proven to be an effective strategy for entering the market, with companies like AstraZeneca, Roche, Novartis, and Sanofi incorporating companion diagnostics into 60–80% of their clinical portfolios. This approach is likely to lead to medications equipped with wearable technology or apps, enabling patients to monitor crucial health parameters and manage their conditions in the era of personalized and precision medicine[1-6].

This review aimed to explore the modern advancements of the pharmaceutical industry, examining the new technological methods that have contributed significantly to its growth and prosperity. In recent years, innovations such as artificial intelligence (AI), machine learning, advanced robotics, and biotechnology have revolutionized key areas, including drug discovery, production, and distribution.

II. Objective and Research Questions

The purpose of this review is to evaluate the development of the pharmaceutical industry and address the following research queries in a critical manner:

1. How has the pharmaceutical industry evolved over time?
2. What are the key challenges faced by industry?
3. What emerging trends are shaping the future of the pharmaceutical industry?

Abbreviations and Acronyms

(DL)	deep learning
(AI)	artificial intelligence
(IoT)	Internet of Things
(QSPR)	Quantitative Structure-Property Relationship
(ADMET)	absorption, distribution, metabolism, excretion, and toxicity

III. Methodology

A systematic literature search was conducted utilizing various academic databases, including PubMed, Scopus, Google Scholar, and Web of Science. Key search terms included "pharmaceutical industry," "development," "innovation, "challenges," "trends," "artificial intelligence in drug development," "block chain in pharma," "3D printing in drug manufacturing," "robotics in pharmaceutical production, “and "future prospects" were used in combination to retrieve relevant articles. Studies published in the last 5 years (2020–2025) were selected for analysis. Both peer-reviewed journal articles and industry reports were included to provide a well-rounded perspective on the topic.

To ensure the relevance and reliability of the sources used in this review, the following inclusion and exclusion criteria were applied: i) Inclusion criteria, 1. Peer-reviewed research articles, and white papers published in the last decade, 2. Studies investigating the development of the pharmaceutical industry on a global scale, and 3. Papers focusing on the challenges, trends, and future prospects of the industry. ii)Exclusion criteria, 1. non-peer-reviewed articles, opinion pieces, and editorials, and 2. Studies or reports with a regional focus rather than a global perspective.

IV. Results and Discussion

The analysis of the selected studies revealed several key advancements in the pharmaceutical industry due to the integration of modern technologies:

1) Technological advancements in drug discovery

The method of finding new drugs has changed because of technological advancements in data analytics, machine learning, and artificial intelligence (AI). These tools have expedited the discovery of new treatments by forecasting medication efficacy and toxicity as well as finding interesting pharmacological targets [7,8].

AI has the potential to play a role throughout the entire pharmaceutical product development process, spanning from laboratory work to patient care. Its applications include aiding in rational drug design, facilitating decision-making, determining optimal treatment paths for individual patients (including personalized medications), and handling clinical data generated for future drug development. In the marketing arena, executives can employ Eularis' E-VAI, an analytical and decision-making AI platform, to strategically allocate resources for maximal market share acquisition, handle falling sales, and forecast areas for investment. The platform predicts important drivers in pharmaceutical sales by building analytical roadmaps based on competitors, important stakeholders, and current market share using machine learning algorithms and an intuitive user interface [7-9].

Despite the advantages it offers, artificial intelligence faces numerous challenges related to data, encompassing issues such as data size, expansion, diversity, and uncertainty. Pharmaceutical companies, for instance, grapple with vast datasets containing millions of compounds for drug development. Traditional machine learning tools may struggle to manage such extensive and varied data. A quantitative structure-activity relationship (QSAR) computational model offers a quick way to predict many compounds or basic physicochemical characteristics, like log P or log D. But these models are not very good at predicting complex biological features like the potency and side effects of a drug. QSAR-based models also address small training sets, experimental data errors in training sets, and a lack of experimental validations[7]. To assess the safety and effectiveness of drug molecules through extensive data modeling and analysis, modern AI methods like deep learning (DL) and relevant modeling studies prove valuable in addressing these challenges. Merck, in an effort to gauge the impact of deep learning on the pharmaceutical industry's drug discovery, organized a QSAR ML challenge in 2012. The results revealed that, particularly in the context of 15 sets of data related to drug candidate absorption, distribution, metabolism, excretion, and toxicity (ADMET), DL models exhibited markedly superior predictive capabilities compared to conventional machine learning techniques [7,8].

The next step after discovering a new therapeutic molecule is to combine it with a suitable dosage form that has the requisite delivery characteristics. In this field, AI has the potential to replace the conventional trial-and-error method. Leveraging Quantitative Structure-Property Relationship (QSPR), various computational tools can efficiently address formulation design challenges, including concerns related to dissolution, porosity, and stability. Decision-support tools function through a feedback mechanism, overseeing the entire process and making occasional adjustments as needed. These tools determine the type, characteristics, and quantity of excipients by utilizing rule-based systems based on the physicochemical properties of the drug [7-9].

2) Transforming pharmaceutical manufacturing

Automation, robots, and continuous manufacturing have all led to notable improvements in pharmaceutical manufacturing. These innovations have decreased expenses, lowered human error, increased efficiency, and made individualized medicine possible [2,10].

By utilizing cutting-edge manufacturing technologies, the fourth industrial revolution lowers dependency on human intervention by establishing autonomous and self-organizing manufacturing processes. With the help of the automated and digital innovations brought about by Industry 3.0, the pharmaceutical production sector is currently experiencing a significant transition towards Industry 4.0. Whereas Industry 3.0 focuses on quick advancements in specific processes and equipment, Industry 4.0 aims to enhance production infrastructures and systems as a whole. In this situation, algorithms are essential for evaluating performance data and for making business and operational decisions in real time that have an immediate impact on production results[2]. The journey from basic data collection to digital maturity entails capturing raw data from the manufacturing process, analyzing it for valuable information, incorporating artificial intelligence to provide contextual significance, and ultimately transforming that knowledge into actionable insights for informed decision-making. This acquired "wisdom" facilitates self-optimization, judgment, decision-making, remote operations, and adaptive control in autonomous systems and computer algorithm-driven cyber-physical machines [2,10-12].

The emergence of Industry 4.0 compels us to imagine the manufacturing world fully automated and digitalized, as well as the potential effects on pharmaceutical operations and regulations. Digitization, automation, and real-time data integration will enable new operational paradigms that should allow pharmaceutical manufacturing to meet quality standards better than Six Sigma for both small and large-molecule drugs. The COVID-19 epidemic has highlighted the need for production technology that reduces the need for human interaction and can quickly adjust to shifting market conditions. For example, robotics- and automation-based procedures may be necessary when individuals are unable to collaborate closely with one another [2,10,11].

3) Supply chain transformation

As well as, the pharmaceutical supply chain is intricate and vulnerable to a number of problems, such as ineffective inventory control and fake medications. Supply chain transformation sheds light on how big data analytics, blockchain, and the Internet of Things (IoT) are lowering medication shortages, improving visibility, and optimizing supply chain operations [13,14].

IoT is the physical networking of software, embedded systems, and electronic sensors that enable data sharing across a network from any location. IoT's primary contributions to the pharmaceutical industry are its ability to monitor health issues, use evolving technologies to predict future patient-related aspects, transform information, lower costs, and save lives. The primary obstacles in configuring the Internet of Things are related to communication protocols and electronic sensor devices that gather data in any language from the server. A manufacturer's objective is to further remove the pill and synchronize the digital data from the sensor [12-14].

The idea behind the pharmaceutical industry is to use smart connectivity in medical equipment and network topologies to monitor every step of the production process while a patient is being observed clinically. By utilizing cutting-edge technology, IoT can foster positive interactions, lessen uncertainty between patients and the pharmaceutical industry, and provide novel approaches to illness treatment. Automation will result from increased availability and affordability of health-monitoring technology as IoT penetration grows [12,14].

Moreover, the existence of several dealers and middlemen creates a chance for dishonesty that reduces the effectiveness of the supply chain. Blockchain has been praised for its ability to stop the sale of subpar medications. Drugs that don't meet quality standards are seized and their introduction into the pharmaceutical supply chain is investigated. Pharmaceutical distribution is made easier by ledger systems, chain codes, and serialization the process of assigning numbers to pharmaceutical products so they can be identified and distinguished from one another. Blockchain data is strictly controlled to prevent illegal access that might compromise security measures. The pharmaceutical distribution system's IoT increases efficiency [13,14].

It is essential to track and trace goods in transit from the origin to the destination. While delivery delays are detrimental to business operations in various industries, in the pharmaceutical and healthcare sectors, they can lead to severe consequences, including fatalities or aggravation of illnesses. The pharmaceutical supply chain has benefited from the application of blockchain technology. Ensuring regulatory compliance, safeguarding patient health, and optimizing business operations all hinge on the vital aspects of drug tracking and traceability. The seamless and secure transit of goods to their designated destinations is indispensable for the effective functioning of pharmaceutical business and patient management. To streamline the global distribution of medications, a secure worldwide registry has been established. Even smaller businesses should be able to benefit from this technology, despite the fact that it offers significant opportunities for larger pharmaceutical companies [13,14].[15]

4) Personalized medicine and genomics

Thanks to the quick developments in precision medicine, genomics, and genetic testing, the era of personalized medicine has arrived. These technologies make it possible to customize treatment programs for specific patients, accounting for their individual traits and genetic predispositions [16,17].

Treatment plans that are tailored to each patient's unique clinical profile are referred to as personalized medicine. The unique features of each patient are taken into account when modifying the course of treatment, which may end up being more involved than usual. Recent developments in the pharmacological and genetic properties of different pharmaceuticals highlight the possibility that individual genetic variations may result in variations in how each person reacts to medication[16]. Personalized medicine is a notion that is confronting challenges from multiple angles. Providing the relevant treatments to suitable patients is the primary goal of personalized medicine [16,17]. Rapid advancements in high-throughput technologies have led to the addition of a substantial quantity of data pertaining to molecular and cellular biology, offering previously unheard-of insights into a variety of cellular processes. Computational techniques are now able to exploit these massive volumes of data to obtain a better knowledge of patient diagnosis, various underlying illness causes, and possible therapy choices. Based on their responses to medications and treatments, as well as their genetic and epigenomic profiles, computational techniques can divide patients into various subtypes. Many scenarios, such as disease prediction, cancer diagnosis, creating disease decision criteria, and customized recommendation systems, can benefit from this classification. These developments have prompted numerous research teams to use computational methods to look into various facets of personalized medicine, including pharmacogenomics, prognosis, and diagnosis [16]. Big data in the medical field has the potential to lead to the discovery of novel drugs. Healthcare professionals can determine the possible advantages and disadvantages of clinical trials or therapeutic processes by employing prior data record, real-time, predictive metrics, and cohesive mix data visualization techniques. Furthermore, big data analytics in healthcare can be crucial to the creation of novel, ground-breaking medications and inventive, progressive treatments through data-driven analysis of genetic data and effective patient predictions. In the healthcare industry, data analytics can simplify, innovate, offer security, save lives, and provide clarity and confidence [16,17].

5) Telemedicine and digital health solution

Furthermore, Patient care has changed as a result of the broad use of telemedicine and digital health technologies, particularly in rural areas. We look at how technologies like wearables, mobile apps, telehealth platforms, and remote monitoring systems can improve patient outcomes and accessibility to healthcare[18,19].

To assess the health of a remote patient efficiently, telehealth and telemedicine practitioners must conduct electronic face-to-face interactions between patients and specialists. Telehealth services are provided through two models: business-to-business (B2B) and direct-to-consumer (D2C). In the B2B model, patients can engage in electronic discussions about their health concerns with doctors, while in the D2C model, caregivers can remotely join consultations and medical education services, including patient surgeries, utilizing tools that facilitate audio and video conferencing. Asynchronous transfer of videos and images, including diagnostic test results like x-rays, aids caregivers in more accurately diagnosing patients' conditions during electronic face-to-face consultations[18,19].

Due to the limited data sharing among health organizations within existing telemedicine systems, the management of patient health records is hindered by isolated silos. Blockchain technology addresses this issue by providing a unified and consistent view of the patient's electronic health record to all relevant parties. The transparency and visibility offered by blockchain enable participating organizations to trace a patient's medical history and suggest suitable treatments. For instance, audit leveraging blockchain technology can ascertain the individuals who accessed electronic records, and the specific transactions conducted[18,19].

6) Regulatory challenges and ethical considerations

Although technology presents opportunities for progress, it also presents ethical and regulatory issues to ensure patient safety and trust, strong regulations, data privacy, cybersecurity, and responsible innovation are necessary [8]. To fully utilize AI in pharmaceutical industry and healthcare, four main ethical issues must be resolved: (1) informed consent to use; (2) safety and transparency; (3) algorithmic fairness and biases; and (4) data privacy [20,21].

7) Future Perspectives

The future of the pharmaceutical industry is hanging to be shaped by deeper integration of advanced technologies, driven by the ongoing need for faster, safer, and more personalized healthcare solutions. As the digital transformation of healthcare continues, several key trends and developments are expected to influence the next phase of pharmaceutical innovation[5,15].

Artificial intelligence is expected to move beyond drug discovery into broader clinical applications. In the near future, AI will likely be used to design individualized treatment plans based on patients' genetic profiles, lifestyle factors, and real-time health data. This shift toward precision medicine will lead to more effective therapies with fewer side effects, improving patient outcomes.[15,22]

Continuous manufacturing, supported by automation and real-time quality monitoring systems, will likely replace traditional batch production. This shift will allow for more flexible, efficient, and scalable production lines, particularly important during pandemics or supply chain disruptions.

The emergence of nanotechnology, 3D printing, gene editing, virtual reality, and augmented reality will further expand the potential for technological transformation and improve the pharmaceutical industry's future. It also covers the significance of ongoing research and development, innovation ecosystems, and collaborations.[15,21,22]

On the other hand, with growing environmental concerns, future pharmaceutical operations are expected to adopt green technologies and sustainable practices. Innovations in biodegradable drug delivery systems, energy-efficient manufacturing, and waste reduction strategies will be vital for achieving long-term sustainability goals.

V. Conclusion

Modern technological advancements have undeniably transformed the pharmaceutical industry. From AI in drug discovery to blockchain in supply chain management, these innovations have significantly improved the efficiency, accuracy, and customization of pharmaceutical services and products. As the industry moves forward, the continued integration of these technologies will likely enhance drug development timelines, reduce costs, and improve overall healthcare outcomes. However, addressing regulatory, financial, and technical barriers will be crucial for ensuring the widespread adoption of these technologies across the global pharmaceutical landscape. The pharmaceutical industry is at the forefront of healthcare innovation as technology advances. The industry is positioned to overcome present obstacles, enhance patient outcomes, and propel the creation of innovative therapies and treatments through the integration of emerging technologies.

It is imperative that researchers, industry stakeholders, and policymakers work together to create an atmosphere that supports the responsible adoption and application of these technologies. Technological developments are reshaping the pharmaceutical sector and opening the door to new possibilities in personalized medicine, precision manufacturing, drug discovery, and improved patient care.

References

(1) Reinhardt, I. C.; Oliveira, J. C.; Ring, D. T. *Journal of Industrial Information Integration* **2020**, *18*, 100131.

(2) Arden, N. S.; Fisher, A. C.; Tyner, K.; Yu, L. X.; Lee, S. L.; Kopcha, M. *International journal of pharmaceutics* **2021**, *602*, 120554.

(3) Altıparmak, S. C.; Yardley, V. A.; Shi, Z.; Lin, J. *Journal of Manufacturing Processes* **2022**, *83*, 607.

(4) Nile, S. H.; Baskar, V.; Selvaraj, D.; Nile, A.; Xiao, J.; Kai, G. *Nano-micro letters* **2020**, *12*, 1.

(5) Bashirynejad, M.; Soleymani, F.; Nikfar, S.; Kebriaeezadeh, A.; Majdzadeh, R.; Fatemi, B.; Zackery, A.; Zare, N. *DARU Journal of Pharmaceutical Sciences* **2024**, *33*, 6.

(6) Sultana, N.; Ali, A.; Waheed, A.; Aqil, M. *Materials Today Communications* **2024**, *38*, 107987.

(7) Martin, O. *Advanced Sciences* **2021**, *3*, 1.

(8) Sadybekov, A. V.; Katritch, V. *Nature* **2023**, *616*, 673.

(9) Jiménez-Luna, J.; Grisoni, F.; Weskamp, N.; Schneider, G. *Expert opinion on drug discovery* **2021**, *16*, 949.

(10) Sharma, M.; Sehrawat, R.; Luthra, S.; Daim, T.; Bakry, D. *IEEE Transactions on Engineering Management* **2022**.

(11) Srai, J. S.; Margolles, A. C.; Guo, D. *International Journal of Production Research* **2025**, 1.

(12) Zakari, N.; Al-Razgan, M.; Alsaadi, A.; Alshareef, H.; Alotaibi, S.

(13) Choudhury, S. N.; Gohain, M. In *Evolving Landscapes of Research and Development:*

Trends, Challenges, and Opportunities; IGI Global Scientific Publishing: 2025, p 209.

(14) Singh, M.; Sachan, S.; Singh, A.; Singh, K. K. *Emergence of pharmaceutical industry growth with industrial IoT approach* **2020**, 195.

(15) Miozza, M.; Brunetta, F.; Appio, F. P. *Technological Forecasting and Social Change* **2024**, *207*, 123580.

(16) Hassan, M.; Awan, F. M.; Naz, A.; deAndrés-Galiana, E. J.; Alvarez, O.; Cernea, A.; Fernández-Brillet, L.; Fernández-Martínez, J. L.; Kloczkowski, A. *International journal of molecular Sciences* **2022**, *23*, 4645.

(17) Agyeman, A. A.; Ofori-Asenso, R. *Journal of Pharmacy and Bioallied Sciences* **2015**, *7*, 239.

(18) Ahmad, R. W.; Salah, K.; Jayaraman, R.; Yaqoob, I.; Ellahham, S.; Omar, M. *International journal of medical informatics* **2021**, *148*, 104399.

(19) Lareyre, F.; Chaptoukaev, H.; Kiang, S. C.; Chaudhuri, A.; Behrendt, C.-A.; Zuluaga, M. A.; Raffort, J. *Journal of Clinical Medicine* **2022**, *11*, 6047.

(20) Gerke, S.; Minssen, T.; Cohen, G. In *Artificial intelligence in healthcare*; Elsevier: 2020, p 295.

(21) Marques, C. M.; Moniz, S.; de Sousa, J. P.; Barbosa-Povoa, A. P.; Reklaitis, G. *Computers & Chemical Engineering* **2020**, *134*, 106672.

(22) Haider, R. *J. Pharm. Pharmacol. Res* **2023**, *6*, 1.